The official announcement of the numerical value in performance of the hyper specification will be publicized. -The performance evaluation of the mining machine, “KAMIKAZE” equipped with the 7nm ASIC chip […]
Ranked No. 1 in Manufacturing of PCB Handling Equipment in Korea 31/05/2018 — SEOUL, South Korea — (BUSINESS WIRE) YJ Link Co., Ltd., a company specializing in the manufacturing of […]
26/04/2018 — HAMILTON, Bermuda — (BUSINESS WIRE) Jeffrey Gannon and Adrian Dunner, in partnership with investment vehicles managed by Wafra Inc., today announced the formation of Global Container International LLC […]
Announces significant stake in Hyundai Mobis, Hyundai Motor, and Kia Motors Seeks stronger commitment to governance improvements and enhanced capital returns 03/04/2018 — HONG KONG — (BUSINESS WIRE) Elliott Advisors […]
New Gameplay Preview Video Footage Shows Google Maps API in Action 19/03/2018 — SEOUL, South Korea — (BUSINESS WIRE) The recently announced Ghostbusters World, developed in collaboration between Sony Pictures […]
10/02/2018 — PYEONGCHANG, Korea & HANGZHOU, China — (BUSINESS WIRE) Alibaba Group (NYSE:BABA), the world’s largest retail commerce company, kicked off its first Olympic Games as a TOP partner today […]
22/09/2017 — SEOUL, South Korea — (BUSINESS WIRE) Mobile RPG “King’s Raid” which was launched in February in Korea, North America and SEA, is officially launching in European Markets (Google […]
Samsung Bioepis’ Flixabi® receives positive opinion from the Committee for Medicinal Products for Human Use, meets the European Medicines Agency’s requirements on the quality, efficacy and safety of biosimilars Flixabi® […]
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Benepali® – a biosimilar referencing Enbrel® (etanercept), also known as SB4 – for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and plaque psoriasis. The EC approval follows a positive opinion on Benepali® by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which was announced on November 20, 2015.
The Estée Lauder Companies Inc. (NYSE:EL) announced today that it has completed its investment in Have & Be Co. Ltd., the South Korean company behind skin care brands Dr. Jart+ and Do The Right Thing. Terms of the investment were not disclosed. Launched online in 2005 by ChinWook Lee, Dr. Jart+ is a Seoul-based, global high-growth skin care brand featuring quality and innovative products designed to address specific skin care needs. The brand’s unique fusion of dermatological science and art – as reflected in the brand name, which is inspired by the phrase “Doctor Joins Art” – appeals to a broad range of consumers, especially millennials. Dr. Jart+ is sold in many countries around the world, primarily in Asia and the United States, through various department stores, specialty-multi and e-commerce channels including Sephora.